The FDA has rejected a biologics license application for apitegromab to treat spinal muscular atrophy, according to ...

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with ...

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and ...

Scholar Rock navigates FDA's Complete Response Letter for Apitegromab, aiming for swift resubmission to address spinal ...

Scholar Rock (SRRK) intends to resubmit the apitegromab Biologics License Application (BLA) upon resolution of Catalent Indiana LLC-related observations CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...

Regeneron gests US FDA approval for Libtayo as an adjuvant treatment of CSCC with a high risk of recurrence after surgery and radiation: Tarrytown, New York Friday, October 10, 20 ...

Northern Indiana Public Service Company LLC (“NIPSCO”) announced Oct. 1 that additional energy assistance programs are now open for enrollment to income-eligible customers struggling to pay their ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.

President Donald Trump could soon move to cancel more than $1 billion in federal grants for General Motors Co. and Stellantis ...